Company: NDRA
Filing Date: 2025-07-16
Form Type: S-1/A
Source: 0001654954-25-008117
Chunk: 15

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-07-16
Form: S-1/A
Chunk 15
---
 be materially and adversely affected, and the market price of our common stock could decline. As a result, you could lose some or all of any investment you may make in our securities.

Risks Related to this Offering and Our Securities

We have a history of operating losses and will need to raise significant additional capital to continue our business and operations. If we are unable to raise sufficient capital in this Offering and additionally in the near term to meet our capital and operating needs, we may be forced to further delay, reduce or eliminate our operating activities, or cease operations entirely, which would have a material adverse effect on our business and cause you to lose all of your investment.

We are experiencing financial and operating challenges. As of March 31, 2025, we had $2.1 million of cash and cash equivalents. As disclosed in our auditor’s report on our financial statements filed with our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, there is substantial doubt about our ability to continue as a going concern and, to remain viable, we will require significant additional liquidity in order to execute our business plan. Any inability to raise adequate funds on commercially reasonable terms and in the near term would have a material adverse effect on our business, results of operation and financial condition, including the possibility that a lack of funds causes our business to fail and liquidate. You must be prepared to lose all of your investment.

The issuance of the shares of common stock and Pre-Funded Warrants covered by this prospectus could significantly increase the total number of shares of common stock issued and outstanding and thereby cause our existing stockholders to experience substantial dilution.

The shares being offered pursuant to this prospectus represent 15,700,000 shares of common stock being sold pursuant to this prospectus, and 628,000 shares of common stock issuable upon the exercise of the Underwriter Warrants (or 18,055,000 shares of common stock and 722,200 shares of common stock issuable upon the exercise of the Underwriter Warrants if the Underwriter exercises its over-allotment option in full). As of July 15, 2025, there were 752,755 shares of common stock issued and outstanding (prior to any deemed issuance of the Pre-Funded Warrants and the Underwriter Warrants). If we are required to issue the maximum number of shares of common stock that are being registered hereunder, the number of shares of common stock issued and outstanding after such issuance would represent approximately